1 Racial differences in propranolol enantiomer kinetics following oral dosing were previously documented in our laboratory. The purpose of this study was to more completely describe propranolol kinetics in black and white subjects with the goal of gaining a better understanding of the mechanism(s) responsible for racial differences in oral propranolol kinetics. 2 Twelve white and 13 black healthy males were included in the study. Poor metabolizers of dextromethorphan and mephenytoin were excluded. Subjects took oral propranolol 80 mg every 8 h for 16 doses and received an intravenous dose of radiolabelled propranolol with the 16th dose. Serum and urine samples were collected for 24 h after the 16th dose. Serum concentrations of R-and S-propranolol and urine concentrations of its three primary metabolites were determined by h.p.l.c. 3 Apparent oral clearances of R-and S-propranolol were higher (P<0.05) in blacks than whites ( R-propranolol: 5036±4175 ml min−1 vs 2854±879 ml min−1; S-propranolol 3255±1723 ml min−1 vs 2125±510 ml min−1; blacks vs whites). 4 R-and S-propranolol clearances were higher in blacks than whites (R-propranolol 1069±316 ml min−1 vs 841±161 ml min−1; S-propranolol 947±271 ml min−1 vs 771±142 ml min−1; blacks vs whites, P<0.05). 5 There were trends (P>0.05<0.10) toward higher side chain oxidation, 4-hydroxylation and R-propranolol glucuronidation in blacks compared with whites. Ethnic differences in the enantiomeric ratios of partial metabolic clearance values were not observed. 6 We conclude the higher propranolol oral clearances in black subjects are explained by blacks having slightly higher hepatic metabolism via all three of its major metabolic pathways. Higher propranolol clearances among black subjects were also observed and we conclude this finding is explained largely by the higher hepatic metabolism, but also by slightly higher liver blood flow among black subjects.
Introduction
significantly lower plasma concentrations of both enantiomers of propranolol [1 ] . The lower concentrations translated into 51% and 34% higher apparent oral We have previously shown that following administration of equal oral doses of propranolol, black subjects have clearances (CL o ) of R-and S-propranolol, respectively, in black subjects as compared with white subjects. These racial differences were consistent with previously pub-after oral administration and is metabolized almost pass metabolism, absolute bioavailability and probably clearance (CL) [ 5] . Thus we evaluated both intravenous exclusively by the liver [4 ] . For a drug with these characteristics, the venous equilibration model predicts (i.v.) and oral pharmacokinetics so that all these parameters could be determined. Because propranolol that CL o of unbound drug is the same as intrinsic clearance [4, 5] . Thus, the higher CL o values of propranexhibits nonlinear hepatic first pass metabolism [7, 8] , calculations of propranolol bioavailability and clearance olol observed in our previous study suggested there may be racial differences in its hepatic drug metabolism. The would be flawed unless concentrations of drug in the liver were identical following administration by oral and overall objective of the current study was to describe more adequately the pharmacokinetics of propranolol i.v. routes. In order to accomplish this experimental condition, we simultaneously administered unlabelled in blacks and whites with the goal of gaining a better understanding of the mechanism responsible for the oral propranolol and 3H-labeled i.v. propranolol. racial differences in kinetics following oral propranolol administration.
Propranolol is metabolized to at least 14 metabolites through three major pathways: glucuronidation, side chain oxidation and ring oxidation (Figure 1 ) [6 ] . The Methods major urinary metabolites of these pathways are propranolol glucuronide (PG), naphthoxylactic acid (NLA) Subjects and 4-OH propranolol (HOP), respectively, with HOP undergoing further conjugation to 4-OH propranolol Thirteen African-American males and 13 Caucasian males participated in the study. Women were excluded sulfate (HOPS) and 4-OH propranolol glucuronide (HOPG) [6] . These metabolites (PG, NLA, HOPS and because of restrictions on administering a radiolabelled compound to women of child-bearing potential. Sub-HOPG) have been shown to account for approximately 70% of a propranolol dose and are excellent markers sequent to completion of the study, it was learned that one Caucasian subject was a smoker and his data were for their respective pathways [6] . We hypothesized that racial differences in propranolol CL o were a result of excluded from the analysis of the study. All other subjects were non-smokers and healthy as determined differences in hepatic enzyme activity through one or more of the major metabolic pathways and so in the by medical history, physical examination, routine laboratory evaluation and 12 lead electrocardiogram. Subjects current study we characterized metabolism through these pathways.
gave written, informed consent prior to participation in the study. The study was approved by the Institutional Racial differences in hepatic enzyme activity would also be expected to produce racial differences in first Review Board at The University of Tennessee, Memphis. All studies were conducted at the University of Tennessee on the radioactivity present in the 10 ml samples and the total volume of solution injected. HOP) and side chain oxidation (formation of NLA) of non-heparinized blood collection tubes, allowed to clot, centrifuged and the serum separated and stored at propranolol, respectively [ 9] . Since both enzymes are known to exhibit genetic polymorphisms [ 10] , the −20°C until analysis. An additional 10 ml blood sample was collected at 4 h into a heparinized blood collection pharmacogenetic phenotypes for both enzymes were determined in all subjects prior to their inclusion in the tube for determination of blood concentration. The blood-serum ratio (B/S ratio) was calculated as the study. Pharmacogenetic phenotypes for CYP2D6 and CYP2C19 were determined using dextromethorphan ratio of the concentration of propranolol in blood and serum at the 4 h time point. Urine was collected for the and rac-mephenytoin, respectively, as probes, using slight modifications of previously published methods same 24 h period (in two 12 h collections) into bottles containing 2 g of (-)ascorbic acid to prevent oxidation [ 11, 12] . Extensive metabolizers (EMs) of dextromethorphan were identified by a dextromethorphan/dextrorof the hydroxylated metabolites. Total urine volume from each collection period was measured and an phan ratio <0.3 and EMs of mephenytoin were identified by a S/R mephenytoin ratio <0.8. Subjects aliquot frozen at −20°C until analysis. phenotyped as poor metabolizers (PMs) for either enzyme were excluded from the study.
Assay methods
Propranolol enantiomer serum concentrations were Study protocol determined by h.p.l.c. with a chiral stationary phase, using a published method from our previous study; Subjects took oral rac-propranolol HCl 80 mg every 8 h for 14 doses on an out-patient basis and recorded the pronethalol was used as the internal standard [ 1]. The lower limit of detection was 5 ng ml−1; within day CVs time at which each dose was taken. Subjects abstained from alcohol or caffeine containing food or beverages were <2% and between day CVs were <5% for low and high controls. Eluent fractions corresponding to Rfor 24 h before and during the in-patient study period. Subjects also refrained from using any other medications and S-propranolol chromatographic peaks were collected into individual scintillation vials and samples during the entire study. On the night before the study, subjects were admitted to the Clinical Research Center were counted for radioactivity present by liquid scintillation counting (Beckman LS 6000TA, Beckman and received the 15th oral dose of propranolol 80 mg at 23.00 h. The following morning, one indwelling Instruments Inc., Fullerton, CA, USA). Radioactive counts from liquid scintillation counting were used to venous catheter was inserted into a forearm vein of each arm. One catheter was used for infusion of radiolabelled determine concentrations (d min−1 ml−1) from the [3H]-propranolol i.v. dose. propranolol (described below) and the second catheter was used to obtain blood samples. Subjects received the Urine concentrations of R-and S-PG and R-and S-HOP were determined by h.p.l.c. with slight modifi16th oral dose of propranolol 80 mg at 07.00 h. Subjects fasted from 8 h before until 4 h after receiving the cations of an assay published from our laboratory, using pronethalol as the internal standard [ 13] . Lower limits 16th dose.
An intravenous dose of radiolabeled rac-propranolol of detection were 0.1 mg ml−1 (5 ng) for PG enantiomers and 0.2 mg ml−1 (10 ng) for HOP enantiomers. Within (rac- [4-3H] propranolol HCl, specific activity 19.4 Ci mmol−1, radiochemical purity determined by h.p.l.c.:
day CVs were all <5% and between day CVs were all <10%. HOPG, HOPS and PG were deconjugated with 98.7%, Amersham Life Science, Arlington Heights, IL, USA) was infused over 2 min just prior to 16th dose.
200 mL of a b-glucuronidase/aryl sulphatase mixture (Sigma G-0751, Sigma Chemical Company, St Louis, The radiolabelled propranolol was diluted in normal saline prepared for parenteral administration in 10 ml, MO, USA) containing 20 000 units b-glucuronidase and 740 units of sulphatase activity per ml of solution at single dose vials by the Sterile Products Laboratory, Department of Pharmaceutical Sciences, University of 37°C for 12-14 h to release the glucuronide and sulphate conjugates. Preliminary experiments suggested that Tennessee College of Pharmacy. Two 10 ml aliquots were taken from each vial and the radioactive content deconjugation of glucuronide conjugates was complete within about 1 h of incubation while deconjugation of determined by liquid scintillation counting. Approximately 10 ml of radioactive drug solution was then sulphate reached a plateau after 8 h. Other experiments showed the amounts of 4-OH propranolol and propranwithdrawn from the vial into a plastic syringe. The syringe was weighed before and after administration to olol were stable from 12 to 24 h of incubation (data not shown). determine the exact volume of radioactive solution administered. The radioactive dose was calculated based Urine concentrations of NLA were measured by a previously published h.p.l.c. technique [ 14] which was Volume of distribution at steady-state of unbound drug (V ss,u ) was calculated as V ss /f u,b , hepatic extraction ratio validated in our laboratory. The lower limit of detection for this assay was 0.1 mg ml−1 (5 ng) and within day (E) was calculated as 1-F and hepatic blood flow (Q H ) was calculated by Q H =CL/E. The assumptions made and between day CVs were <3% and <6%, respectively. Individual enantiomer concentrations of NLA in performing these final two calculations were that propranolol is completely metabolized by the liver (e.g. were not determined because Ward et al. [9] metabolites was related to the 80 mg propranolol HCl dose as per cent dose recovered to obtain a relative
estimate of the fraction of drug absorbed ( f a ) for (equation 2) comparison between black and white subjects. The purpose of estimating a relative f a in the current study where C p.o.i is the ith coefficient following administration was not to determine an accurate value for f a , but rather of the 16th oral dose of propranolol, t lag is the absorption to be able to assess whether the fraction absorbed was lag time and t is the dosing interval (8 h). l 1 was similar in the two groups. Finally, S/R enantiomeric designated as k a (apparent first order absorption rate ratios were calculated for CL o , CL, V ss , V ss,u , t 1/2 , F, Q H , constant). Equations 1 and 2 were fitted simultaneously CL m (HOP, PG), and f u,b . to the intravenous and oral serum concentration time data by weighted least squares regression using the computer program NONLIN ( Vax Version 3.0, SCI Software, Lexington, KY, USA). Concentrations of RStatistical methods and S-propranolol enantiomers were fitted separately. Weights were assigned as 1/observed concentration.
The sample size was determined by statistical power NONLIN provided estimates of the coefficients, analysis assuming an a of 0.05 and a b of 0.20 to exponents and t lag . The coefficients were converted from detect a 35% difference in CL o , based on data from our serum to blood concentrations using the B/S ratio. previous study [1] . Statistical comparisons between Clearance (CL ), volume of distribution at steady-state black and white subjects were made using a one-tailed, of total drug (V ss ), and elimination half-life (t 1/2 ) were unpaired t-test with equal or unequal variances, as calculated by standard equations [15 ] . Apparent oral appropriate. A one-tailed t-test was performed because clearance (CL o ) and systemic bioavailability (F ) were the direction of the difference between black and white determined as follows: subjects was known to us a priori, based on data from our previous study [1 ] . 95% confidence intervals for of R-and S-propranolol were 27% and 23% higher (P<0.05), respectively, in black subjects as compared vs white) of subjects did not differ between groups. Individual fits for R-and S-propranolol serum with white subjects. Median and range values of k a for R-and S-propranolol were 1.04 (0.54-9.48) and 1.06 concentration vs time data in a representative subject are shown in Figure 2 . For all subjects, 33% of the (0.65-6.97) h−1 in black subjects and 1.26 (0.87-2.09) and 1.55 (1.02-2.23) h−1 in white subjects. Median and fitted data points were within 5% of the observed data points, 60% were within 10%, 74% were within range values of t lag for R-and S-propranolol were 0.55 (0.36-1.47) and 0.49 (0.38-0.99) h in black subjects and 15%, 83% were within 20% and 89% were within 25%.
0.46 (0.34-0.92) and 0.43 (0.27-1.32) h in white subjects. Mean B/S ratios for S-propranolol were 0.86 in both Mean pharmacokinetic parameter estimates for pro- blacks and whites and for R-propranolol were 0.87 in kinetics reveals estimated Q H of 1241±277 ml min−1 in white subjects versus 1449±327 ml min−1 in black blacks and 0.89 in whites.
Partial metabolic clearances (CL m ) of propranolol to subjects (P<0.05). Although CL and CL o remained different when corrected for body weight, the difference its three major metabolites after oral dosing are shown in Table 2 . These data reveal there were trends (P values in Q H was largely explained by the small (non-significant) differences in body weight between the two groups. between 0.05 and 0.10) toward higher CL m to R-and S-HOP, NLA and R-PG in black subjects compared When Q H was corrected for body weight, racial differences in Q H were no longer significant (17.1 ml with white subjects. Metabolism to both HOP and PG exhibited significant stereoselectivity in both groups.
min−1 kg−1 in blacks vs 15.7 ml min−1 kg−1 in whites). V ss of both R-and S-propranolol were higher in Figure 3 depicts the relationship between S-propranolol CL o and CL M to S-HOP. The relationship blacks than whites. Unbound fraction of propranolol was also higher in black subjects than in white subwas highly correlated and statistically significant in black subjects but not white subjects. Similar obserjects (P<0.05 for S-propranolol and P=0.056 for R-propranolol). When the contribution of plasma vations were made for the relationship between R-propranolol CL o and CL m to R-HOP (data not protein binding on V ss was taken into account, the V ss of unbound propranolol (V ss,u ) was not different between shown). The opposite was seen for the relationship between propranolol CL o and CL m to NLA (blacks: r= the two groups, suggesting that tissue binding of propranolol does not differ between black and white 0.243, P=0.45; whites: r=0.837, P=0.001). Significant correlations between propranolol CL o and CL m to PG, subjects. Stereoselectivity was observed in several of the kinetic for both R and S enantiomers were observed in both groups and there were no racial differences in these parameters of propranolol (specifically CL o , CL, F, V ss , CL m -HOP and CL m -PG) however, there were no racial correlations (data not shown).
Calculation of Q H based on racemic propranolol differences in any of the enantiomeric ratios. Discussion striking. While the variability in CL m to HOP accounted for 83% of CL o variability among blacks, the same relationship was non-significant among whites. In the current study we confirmed the results of our previous study [ 1] that CL o for both propranolol Conversely, variability in CL m to NLA accounted for 70% of CL o variability among whites, yet was a nonenantiomers was higher in healthy black men than in healthy white men. Based on the results of our original significant relationship among blacks. The precise meaning of these racial differences in correlations study, our hypothesis for the current study was that the racial differences in CL o were due to differences in is unclear.
As could be predicted from the venous equilibration hepatic drug metabolism. To assess differences in metabolism in the current study, we determined partial model, CL of both propranolol enantiomers was higher in black subjects than in white subjects. Since propranometabolic clearances for propranolol's three major metabolites. We originally anticipated the observed lol is a moderately high extraction drug, its CL is dependent on both hepatic metabolism (intrinsic clearracial differences in CL o would be explained by large differences in one metabolic pathway. However, rather ance) and also on liver blood flow [4, 5] . We conclude that most of the observed difference in CL is explained than observing large differences in a single pathway, we observed smaller differences in all three pathways. All by differences in hepatic metabolism. However, the small (approximately 9%) differences in weight-corrected Q H three metabolic pathways (NLA, R-and S-HOP and R-PG) exhibited trends toward higher activity in blacks also appear to contribute to the racial differences in propranolol CL. than whites (P values between 0.05 and 0.10). These data suggest that racial differences in CL o are likely Somewhat surprising was the lack of difference in absolute F. Since the aspect of F we expected to differ explained by slightly higher hepatic metabolism via all three propranolol metabolic pathways among blacks.
between blacks and whites was first pass metabolism, we needed to determine that extent of absorption of These findings of slightly higher metabolism lead to questions about specific enzymes which may exhibit propranolol was similar in the two groups. The per cent of dose accounted for (relative fa) was not significantly different activities between black subjects and white subjects, particularly the cytochrome P450 enzymes. As different between groups and averaged 80% in blacks and 87% in whites. Since relative fa and absolute F described earlier, CYP2D6 is an important enzyme responsible for metabolism of propranolol to HOP.
were not different between the two groups, we conclude there were also no differences in hepatic first pass Data from other studies suggest that CYP2D6 accounts for 50 to 90% of total propranolol 4-hydroxylation, metabolism. The determinants of first pass metabolism are intrinsic clearance and Q H in the following relationwith the remaining 10-50% of propranolol 4-hydroxylation occurring via another CYP enzyme (s) ship (according to the venous equilibration model):
We conclude the lack of difference in [ 9, [16] [17] [18] . Based on this, one reasonable hypothesis is that there may be racial differences in CYP2D6 activity.
F between blacks and whites is the consequence of differences in Q H partially offsetting the differences in To test this hypothesis, we recently completed a study in which we compared CYP2D6-mediated metabolism intrinsic clearance or drug metabolism. in blacks and whites, using metoprolol with and without quinidine as the probe drug [19] . Data from that study sible for formation of the initial product of side chain oxidation (desisopropylpropranolol, DIP) (not shown in Figure 1 ) [17, 18] . Differences in urinary NLA concenReferences trations between CYP2C19 (mephenytoin hydroxylase) EMs and PMs suggest CYP2C19 may be responsible 1 Johnson JA, Burlew BS. Racial differences in propranolol for conversion of the initial metabolite (DIP) to NLA pharmacokinetics. Clin Pharmacol T her 1992; 51: 495-500. [ 9] . Racial differences in the activity of either of these The relationships between CL o and CL m to HOP
